In order to exclude that reduced ACh levels in serum may dependent also on deficiency in synthesis and release, we have evaluated the expression of the ACh biosynthetic enzyme, ChAT, and of the non-vesicular ACh transporters OCTN-1 and mediatophore [10,32] in RR-MS patients. This evidence concerns the gene SLC22A4 and myeloid sarcoma.